"VSports在线直播" Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology
- PMID: 23335040
- PMCID: "V体育ios版" PMC3641622
- DOI: V体育平台登录 - 10.2215/CJN.09570912
"V体育2025版" Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology
Abstract
Background and objectives: Circulating fibroblast growth factor-23 is associated with adverse cardiovascular outcomes in CKD and non-CKD individuals, but the underlying mechanism remains unclear VSports手机版. This study tested whether this association is independent of mineral metabolism and indices of subclinical cardiovascular pathology. .
Design, setting, participants, & measurements: The prospective association between fibroblast growth factor-23 and major cardiovascular events (a composite of hospital-treated myocardial infarction, hospital-treated stroke, or all-cause mortality) was investigated in the community-based Prospective Investigation of the Vasculature in Uppsala Seniors (n=973; mean age=70 years, 50% women) using multivariate logistic regression V体育安卓版. Subjects were recruited between January of 2001 and June of 2004. .
Results: During follow-up (median=5. 1 years), 112 participants suffered a major cardiovascular event. In logistic regression models adjusted for age, sex, and estimated GFR, higher fibroblast growth factor-23 was associated with increased risk for major cardiovascular events (odds ratio for tertiles 2 and 3 versus tertile 1=1. 92, 95% confidence interval=1. 19-3. 09, P<0. 01). After additional adjustments in the model, adding established cardiovascular risk factors, confounders of mineral metabolism (calcium, phosphate, parathyroid hormone, and 25(OH)-vitamin D), and indices of subclinical pathology (flow-mediated vasodilation, endothelial-dependent and -independent vasodilation, arterial stiffness, and atherosclerosis and left ventricular mass) attenuated this relationship, but it remained significant (odds ratio for tertiles 2 and 3 versus tertile 1=1. 69, 95% confidence interval=1. 01-2. 82, P<0 V体育ios版. 05). .
Conclusions: Fibroblast growth factor-23 is an independent predictor of cardiovascular events in the community, even after accounting for mineral metabolism abnormalities and subclinical cardiovascular damage. Circulating fibroblast growth factor-23 may reflect novel and important aspects of cardiovascular risk yet to be unraveled. VSports最新版本.
V体育官网入口 - References
-
- Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205–2215, 2005 - PubMed
-
- Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429–435, 2004 - PubMed
-
- Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272–2279, 2003 - PubMed
Publication types
- Actions (VSports手机版)
MeSH terms
- VSports在线直播 - Actions
- "VSports app下载" Actions
- VSports手机版 - Actions
- Actions (VSports注册入口)
- "V体育安卓版" Actions
- "VSports注册入口" Actions
- Actions (V体育官网)
- Actions (VSports)
- "VSports" Actions
- "V体育官网入口" Actions
- Actions (V体育安卓版)
- Actions (V体育官网)
- VSports app下载 - Actions
Substances
- "V体育官网" Actions
- Actions (VSports手机版)
- Actions (V体育官网)
- Actions (V体育官网入口)
"V体育平台登录" LinkOut - more resources
Full Text Sources (V体育官网入口)
Other Literature Sources (VSports)
Medical